Opendoor Technologies Inc vs uniQure N.V. Ordinary Shares — how do they compare? Opendoor Technologies Inc trades at $1.96 (market cap $2.05B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Opendoor Technologies Inc is the larger of the two by market cap, and uniQure N.V. Ordinary Shares is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Opendoor Technologies Inc for 33 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| OPEN | QURE | |
|---|---|---|
Market Cap | $2.05B | $1.48B |
Volume | 27,619,294 | 2,488,780 |
Sector | Real Estate | Health |
52-Week High | $9.37 | $70.59 |
52-Week Low | $1.99 | $9.03 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $3.12B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
Opendoor Technologies trades at $2.11, down 86% from its peak, with bearish technical signals dominating. The company shows deteriorating fundamentals with revenue declining from $15.6B in 2022 to $4.4B in 2025 while net losses widened to -$1.3B. Recent earnings misses and negative profit margins contrast with analyst optimism, as the stock trades well below the $4.92 consensus target. The mortgage expansion initiative represents a potential growth catalyst amid challenging housing market conditions.
The outlook remains challenging with persistent losses and housing market sensitivity, though deep valuation discount and strategic initiatives offer speculative upside. Key risks include execution missteps, interest rate sensitivity, and competitive pressures in the iBuyer space. Investors face high volatility but potential for significant returns if the turnaround strategy succeeds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →